Akeso Printed Ivonescimab plus Ligufalimab as First-Line Therapy for PD-L1-Optimistic Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at ESMO 2024 By Investing.com
Head-to-Head Section 3 Trial In comparison with Pembrolizumab Initiated HONG KONG, Sept.…
